Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, Groop PH, Pratley RE, Rosas SE, Rossing P, Skyler JS, Tuttle KR, Lawatscheck R, Scott C, Edfors R, Scheerer MF, Kolkhof P, McGill JB. Heerspink HJL, et al. Among authors: lawatscheck r. Diabetes Res Clin Pract. 2023 Oct;204:110908. doi: 10.1016/j.diabres.2023.110908. Epub 2023 Oct 5. Diabetes Res Clin Pract. 2023. PMID: 37805000 Free article. Clinical Trial.
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL; FIDELIO-DKD Investigators. Agarwal R, et al. Among authors: lawatscheck r. J Am Soc Nephrol. 2022 Jan;33(1):225-237. doi: 10.1681/ASN.2021070942. Epub 2021 Nov 3. J Am Soc Nephrol. 2022. PMID: 34732509 Free PMC article. Clinical Trial.
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Fonseca V, Umpierrez GE, Caramori ML, Joseph A, Lambelet M, Lawatscheck R, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Among authors: lawatscheck r. Diabetes Obes Metab. 2023 Feb;25(2):407-416. doi: 10.1111/dom.14883. Epub 2022 Nov 2. Diabetes Obes Metab. 2023. PMID: 36193847 Free PMC article. Clinical Trial.
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Pitt B, Agarwal R, Anker SD, Ruilope LM, Rossing P, Ahlers C, Brinker M, Joseph A, Lambelet M, Lawatscheck R, Filippatos GS; FIDELIO-DKD and FIGARO-DKD Investigators. Pitt B, et al. Among authors: lawatscheck r. JAMA Netw Open. 2022 Oct 3;5(10):e2236123. doi: 10.1001/jamanetworkopen.2022.36123. JAMA Netw Open. 2022. PMID: 36287567 Free PMC article. Clinical Trial.
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, Fried L, Roy-Chaudhury P, Sarafidis P, Ahlers C, Brinker M, Joseph A, Lawatscheck R, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Bakris GL, et al. Among authors: lawatscheck r. Kidney Int. 2023 Jan;103(1):196-206. doi: 10.1016/j.kint.2022.08.040. Epub 2022 Oct 28. Kidney Int. 2023. PMID: 36367466 Free article.
26 results